EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia

Hanna F Nowotny iD, Hannah Choi, Selina Ziegler, Natalie Doll, Ariane Bäuerle, Ann-Christin Welp iD, Ilja Dubinski, Katharina Schiergens, Uta Neumann, Lea Tschaidse, Matthias K Auer, Simon Rothenfusser iD und 2 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041479 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hanna F Nowotny und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Glucocorticoids, Circadian Rhythm. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Eva Luise und Horst Köhler Stiftung, Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) requires lifelong glucocorticoid replacement to manage cortisol deficiency and excessive androgen production. Conventional circadian treatment (CT) tries to mimic natural cortisol rhythms, whereas reverse-circadian treatment (RC) prioritizes the suppression of adrenal androgen excess overnight through evening dosing. Limited data exist on the immunological impact of these regimens. A bi-centric study was conducted, including 41 pediatric and adolescent CAH patients. Peripheral blood samples were collected from patients on conventional treatment (n = 38) or RC (n = 16), with 11 RC patients switching to conventional treatment. Immune cell phenotypes, cytokine profiles, and natural killer (NK) cell cytotoxicity were assessed. Patients receiving RC showed lower percentages of CD4+CD25+ T cells (p = 0.0139). After the switch, patients with RC presented with a higher percentage of non-classical monocytes (p = 0.0255) and a lower percentage of Th17 cells (p = 0.0195). A lower expression of CD107 was observed with RC (p < 0.0001), as well as a higher percentage of NKp30 (p = 0.0189). Comparing patients after the switch from RC to HC, patients with RC presented with a lower NKG2D expression (p = 0.0420). Both conventional treatment and RC exhibited distinct immunological impacts, with CT showing modest advantages in normalizing immune phenotypes. These findings suggest that CT may offer immunological benefits for managing young patients with congenital adrenal hyperplasia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalGlucocorticoidsCircadian RhythmHumansMaleFemaleChildAdolescentImmunophenotypingChild, PreschoolKiller Cells, NaturalInfantCytokines

Stichwörter der Autor:innen

circadiancongenital adrenal hyperplasiaglucocorticoidsimmunophenotype

Substanzen

GlucocorticoidsCytokines

Autor:innen und Institutionen

  • Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Klinik für Pädiatrische Endokrinologie und Diabetologie, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
  • Division of Clinical Pharmacology, LMU University Hospital, LMU Munich, 80337 Munich, Germany.
  • Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, 85764 Oberschleißheim, Germany.

ORCID-Profile: Hanna F Nowotny, Ann-Christin Welp, Simon Rothenfusser

Förderung

  • Deutsche Forschungsgemeinschaft
  • Eva Luise und Horst Köhler Stiftung
  • Else Kröner-Fresenius-Stiftung
  • FlavImmunity
  • French National Research Agency (ANR) project
  • DFG TRR237
  • European Union

Zitieren

APA

Nowotny, H. F., Choi, H., Ziegler, S., Doll, N., Bäuerle, A., Welp, A. C., Dubinski, I., Schiergens, K., Neumann, U., Tschaidse, L., Auer, M. K., Rothenfusser, S., Schmidt, H., & Reisch, N. (2025). Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041479

Vancouver

Nowotny HF, Choi H, Ziegler S, Doll N, Bäuerle A, Welp AC, et al. Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041479

BibTeX
@article{Nowotny2025,
  author = {Nowotny, Hanna F and Choi, Hannah and Ziegler, Selina and Doll, Natalie and Bäuerle, Ariane and Welp, Ann-Christin and Dubinski, Ilja and Schiergens, Katharina and Neumann, Uta and Tschaidse, Lea and Auer, Matthias K and Rothenfusser, Simon and Schmidt, Heinrich and Reisch, Nicole},
  title = {Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041479}
}
Kostenlos starten →